Supernus Pharmaceuticals, Inc. has taken a significant step by filing a post-effective amendment to deregister unissued shares of common stock. This action comes in the wake of its merger with Indivior Pharmaceuticals, which has transformed Supernus into a wholly owned subsidiary of Indivior. The merger, effective November 2, 2026, has led to the delisting of Supernus from the Nasdaq Global Market, marking a new chapter for the company.

Supernus Pharmaceuticals, based in Rockville, Maryland, operates within the pharmaceutical preparations sector (SIC 2834). The company has been publicly traded under the ticker SUPN on the Nasdaq exchange. This recent filing, accession number 0001104659-26-121034, indicates the completion of a merger agreement that was initially entered into on August 1, 2026.

The filing states, "The Company has determined to deregister all of the securities registered under the Registration Statements that remain unsold as of the Effective Time." This means that shares registered under various equity incentive plans are no longer available for issuance, effectively ending the company’s status as a public reporting entity.

The merger could have wide-ranging effects on stakeholders, including employees and shareholders of both Supernus and Indivior. With Supernus now a subsidiary of Indivior, employees may see changes in their stock options and benefits tied to the company’s performance.

Looking ahead, the filing does not specify what the next steps will be for Supernus or Indivior following this merger. However, the pharmaceutical industry will be keenly observing how this merger influences market dynamics and competition.